Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,845.60 | 51.40 | -0.58% |
| CAC 40 | 8,077.80 | 3.63 | -0.04% |
| DAX 40 | 25,408.64 | 142.11 | 0.56% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,695.25 | 15.26 | 0.14% |
| HKSE | 24,510.09 | 251.04 | -1.01% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 66,364.20 | 850.21 | 1.30% |
| NZX 50 Index | 13,811.11 | 13.72 | -0.10% |
| S&P 500 | 7,743.41 | 39.28 | 0.51% |
| S&P/ASX 200 | 8,665.00 | 37.00 | -0.43% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |